David K. Chang
University of Glasgow
CancerInternal medicineSurgeryPathologyOncologyPrecision medicinePancreasMetastasisDiseasePancreatic cancerGemcitabineAdenocarcinomaKRASCancer researchClinical trialCarcinogenesisBioinformaticsMedicineBiomarker (medicine)Biology
Publications 152
#1Stephan Dreyer (Glas.: University of Glasgow)H-Index: 11
#2Rosie Upstill-Goddard (Glas.: University of Glasgow)H-Index: 2
Last. David K. Chang (Glas.: University of Glasgow)H-Index: 48
view all 6 authors...
#1Sneha Vivekanandhan (Mayo Clinic)H-Index: 3
#2Vijay Sagar Madamsetty (Mayo Clinic)H-Index: 8
Last. David K. Chang (Glas.: University of Glasgow)H-Index: 48
view all 12 authors...
PLEXIND1 is upregulated in several cancers, including pancreatic ductal adenocarcinoma (PDAC). It is an established mediator of semaphorin signaling, and neuropilins are its known coreceptors. Herein, we report data to support the proposal that PLEXIND1 acts as a transforming growth factor beta (TGFβ) coreceptor, modulating cell growth through SMAD3 signaling. Our findings demonstrate that PLEXIND1 plays a pro-tumorigenic role in PDAC cells with oncogenic KRAS (KRASmut). We show in KRASmut PDAC ...
#6Lorena TorroniH-Index: 3
#7Chiara Braconi (Glas.: University of Glasgow)H-Index: 28
#1Raphaela Schwappacher (FAU: University of Erlangen-Nuremberg)H-Index: 3
#2Walburga Dieterich (FAU: University of Erlangen-Nuremberg)H-Index: 24
Last. Markus F. Neurath (FAU: University of Erlangen-Nuremberg)H-Index: 134
view all 11 authors...
The evidence that regular physical exercise reduces the risk of developing cancer is well described. However, the interaction between physical exercise and cancer is not fully clarified yet. Several myokines released by skeletal muscle appear to have a direct anti-tumour function. There are few data on myokine secretion after exercise in patients with advanced tumours. Pancreatic cancer (PC) is a very aggressive and usually fatal cancer. To investigate the effects of exercise in PC, the blood of...
#9Anthony J. GillH-Index: 73
#9Euan J. DicksonH-Index: 16
Last. Anubhav MittalH-Index: 23
view all 22 authors...
Background: The long-term outcomes following surgical resection for pancreatic ductal adenocarcinoma (PDAC) remains poor, with only 20% of patients surviving 5 years after pancreatectomy. Patient selection for surgery remains sub-optimal largely due to the absence of consideration of aggressive tumor biology. Objective: The aim of this study was to evaluate traditional staging criteria for PDAC in the setting of molecular subtypes. Methods: Clinicopathological data were obtained for 5 independen...
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Salvatore PaiellaH-Index: 23
Last. Fieke E.M. Froeling (Glas.: University of Glasgow)H-Index: 15
view all 18 authors...
PURPOSETo analyze the prevalence of homologous recombination deficiency (HRD) in patients with pancreatic ductal adenocarcinoma (PDAC).MATERIALS AND METHODSWe conducted a systematic review and meta...
#1Vanessa Lakis (QIMR: QIMR Berghofer Medical Research Institute)H-Index: 3
#2Rita T. LawlorH-Index: 31
Last. Scott Wood (QIMR: QIMR Berghofer Medical Research Institute)H-Index: 19
view all 38 authors...
Here we report the DNA methylation profile of 84 sporadic pancreatic neuroendocrine tumors (PanNETs) with associated clinical and genomic information. We identified three subgroups of PanNETs, termed T1, T2 and T3, with distinct patterns of methylation. The T1 subgroup was enriched for functional tumors and ATRX, DAXX and MEN1 wild-type genotypes. The T2 subgroup contained tumors with mutations in ATRX, DAXX and MEN1 and recurrent patterns of chromosomal losses in half of the genome with no asso...
9 CitationsSource
#1Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
#2Chiara Braconi (Glas.: University of Glasgow)H-Index: 28
Last. Talia Golan (Sheba Medical Center)H-Index: 20
view all 11 authors...
This review summarises the recent evidence on preoperative therapeutic strategies in pancreatic cancer and discusses the rationale for an imminent need for a personalized therapeutic approach in non-metastatic disease. The molecular diversity of pancreatic cancer and its influence on prognosis and treatment response, combined with the failure of "all-comer" treatments to significantly impact on patient outcomes, requires a paradigm shift towards a genomic-driven approach. This is particularly im...
6 CitationsSource
#1Fieke E.M. Froeling (Glas.: University of Glasgow)H-Index: 15
#2Raffaella Casolino (Glas.: University of Glasgow)H-Index: 2
Last. David K. Chang (Glas.: University of Glasgow)H-Index: 48
view all 5 authors...
Substantial progress in recent years has dramatically increased our knowledge of the molecular basis of cancer, revealing new potential therapeutic targets and paving the way for effective personalised medicine for the treatment of many tumour types. However, pancreatic cancer has been lagging behind in this success and continues to be one of the most lethal solid malignancies. Its molecular heterogeneity and the unselected design of the majority of clinical trials to date can in part explain th...
3 CitationsSource
#208Jennifer P. Morton (Glas.: University of Glasgow)H-Index: 54
#209Owen J. Sansom (Glas.: University of Glasgow)H-Index: 90
BACKGROUND & AIMS Continuing recalcitrance to therapy cements pancreatic cancer (PC) as the most lethal malignancy, which is set to become the second leading cause of cancer death in our society. The study aim was to investigate the association between DNA damage response (DDR), replication stress, and novel therapeutic response in PC to develop a biomarker-driven therapeutic strategy targeting DDR and replication stress in PC. METHODS We interrogated the transcriptome, genome, proteome, and fun...
20 CitationsSource